Navigation Links
Researchers identify new compound to treat depression

There is new hope for people suffering from depression. Researchers have identified a compound, hydroxynorketamine (HNK), that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists (ASA). Interestingly, use of HNK may also serve as a future therapeutic approach for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, the authors note.

"The clinical use of ketamine therapy for depression is limited because the drug is administered intravenously and may produce adverse effects such as hallucinations and sedation to the point of anesthesia," said Irving Wainer, Ph.D., senior investigator with the Intramural Research Program at the National Institute on Aging, Baltimore. "We found that the HNK compound significantly contributes to the anti-depressive effects of ketamine in animals, but doesn't produce the sedation or anesthesia, which makes HNK an attractive alternative as an antidepressant in humans."

HNK is one of several different compounds produced when ketamine, an anesthesia medicine-turned-antidepressant, is broken down (metabolized) in the body. Using a rat model, researchers tested HNK to see if the compound alone could produce the same beneficial effects attributed to ketamine without ketamine's unwanted side effects.

In the study, rats were given intravenous doses of ketamine, HNK and another compound produced by ketamine metabolism known as norketamine. The effect each had on stimulating certain cellular pathways of the rats' brains was examined after 20, 30 and 60 minutes. Brain tissue from drug-free rats was used as a control.

Researchers found the compound HNK, like ketamine, not only produced potent and rapid antidepressant effects, but also stimulated neuro-regenerative pathways and initiated the regrowth of neurons in rats' brains. HNK also appears to have several advantages over ketamine in that it is 1,000 times more potent, does not act as an anesthetic agent, and can be taken by mouth, the authors report.

Surprisingly, HNK was also found to reduce the production of D-serine, a chemical found in the body, overproduction of which is associated with neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. HNK's ability to reduce the production of D-serine, while stimulating the regeneration of neuron connections in the brain, may present a potential new therapeutic approach to the treatment of these disorders.

Contact: Theresa Hill
American Society of Anesthesiologists

Related medicine news :

1. Researchers create better methods to detect E. coli
2. UGA researchers discover new method to reduce disease-causing inflammation
3. Ottawa researchers key to new neuromuscular disease care and research network
4. Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
5. Broad Institute, MGH researchers chart cellular complexity of brain tumors
6. Researchers uncover common heart drugs link to diabetes
7. Mayo Clinic researchers discover new form of cancer
8. Researchers recast addiction as a manageable disease
9. Mount Sinai researchers identify protein that keeps blood stem cells healthy as they age
10. Berkeley Lab researchers create nanoparticle thin films that self-assemble in 1 minute
11. Study shows health policy researchers lack confidence in social media for communication
Post Your Comments:
Related Image:
Researchers identify new compound to treat depression
(Date:11/30/2015)... ... November 30, 2015 , ... ... last 15 years, announced today that Michigan-based Family Health Center (FHC) has selected ... over 45 years, FHC was awarded the largest Affordable Care Act grant for ...
(Date:11/30/2015)... ... ... An inventor from Charlottesville, Va., is concerned about the need for peace and ... due to loud noises," she said, "so I decided that there needs to be ... radio waves and microwaves." , The baby BABY MUFF prevents loud noises, radio waves ...
(Date:11/30/2015)... , ... November 30, 2015 , ... In an interview ... role as a top ophthalmologist on Long Island’s east end. During the broadcast, entitled ... in surgery and treatment of glaucoma and cataracts, and how a visit with his ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... just publishing magazines and websites specializing in independent living, assisted living and all ... paramount, and Alzheimer’s awareness and research remains a top priority. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of the leading plastic surgery practices in Florida, is proud to announce that ... for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Belgium , Nov. 30, 2015 ... sciences company focused on developing blood-based diagnostic tests for a ... the Company will present at the LD Micro Conference, which ... Los Angeles, CA. Attending from VolitionRx will be ... Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology: